カテーテル関連血流感染市場：薬剤クラス別、投与経路、適応症、流通チャネル-2025-2030年の世界予測

カテーテル関連血流感染市場は、2023年に16億4,000万米ドルと評価され、2024年には17億4,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には24億6,000万米ドルに達すると予測されています。

カテーテル関連血流感染（CRBSI）はヘルスケア環境における重大な懸念事項であり、予防および治療ソリューションに関する継続的な市場調査が必要です。CRBSIの範囲には、感染源の特定、予防戦略の開発、治療プロトコルの強化が含まれ、感染率の最小化を目指す病院やヘルスケアプロバイダーに影響を与えます。この市場は、カテーテル関連の処置件数の増加や集中治療室における患者の脆弱性の増大により、極めて重要なものとなっています。主な用途には、感染発生率の低減を目的とした高度な抗菌カテーテル、コーティング、ロックソリューションの利用が含まれます。最終用途は主に病院、専門クリニック、外来患者センターに及ぶ。市場成長の原動力となっているのは、安全性を向上させるカテーテル設計やコーティングの技術的進歩であり、カテーテル治療を必要とする慢性疾患の有病率の増加でもあります。

主な成長要因としては、感染管理に対する意識の高まりと厳しい規制ガイドラインが挙げられます。政府の医療支出の増加や研究開発への民間投資の増加を背景に、費用対効果が高く効率的な予防策や治療法の開発には大きな機会があります。しかし、先進医療機器に関連する高コスト、潜在的な副作用、革新的ソリューションのための研究開発の複雑さといった課題にも直面しています。最新の潜在的ビジネスチャンスは、感染リスクの予測分析のためのAIと機械学習の統合、CRBSIのリアルタイムモニタリングのための次世代バイオセンサーの開発を中心に展開しています。

継続的な成長のために、企業はヘルスケア施設とのコラボレーションに焦点を当て、新しいテクノロジーをテストするパイロットプログラムを実施し、実世界での有効性データを収集する必要があります。さらに、研究資金やイノベーション助成金に関するパートナーシップを模索することで、市場導入がさらに促進される可能性があります。とはいえ、保険償還の問題や規制経路の複雑さといった制約が、急速な開発の妨げになる可能性もあります。特に世界の持続可能性動向の中で、カテーテル用の生体適合性で環境に優しい材料の革新は、業界の進歩と市場浸透を促進する有望な研究分野です。CRBSI市場は困難な課題ではあるが、その複雑性を乗り越え、先見的なソリューションに投資できる企業にとってはチャンスに満ちています。

市場力学：急速に進化するカテーテル関連血流感染市場の主要市場インサイトを公開

カテーテル関連血流感染市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 静脈内細菌感染に対する懸念の高まりと効果的な治療オプションの必要性
  • カテーテル関連血流に関する啓発キャンペーンの増加
• 市場抑制要因
  • 医薬品承認に関する政府の厳しい規制と製品回収事例
• 市場機会
  • 細菌性感染症に対する政府の好意的な取り組みと政策
  • ドラッグデリバリーの進歩と新薬開発のための研究開発活動
• 市場の課題
  • カテーテル関連血流感染医薬品に関連するアレルゲンと重大な健康懸念

ポーターのファイブフォース：カテーテル関連血流感染市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：カテーテル関連血流感染市場における外部からの影響の把握

外部マクロ環境要因は、カテーテル関連血流感染市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析カテーテル関連血流感染市場における競合情勢の把握

カテーテル関連血流感染市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスカテーテル関連血流感染市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、カテーテル関連血流感染市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨カテーテル関連血流感染市場における成功への道筋を描く

カテーテル関連血流感染市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 静脈内細菌感染症に対する懸念の高まりと効果的な治療法の必要性
    • カテーテル関連血流に関する啓発キャンペーンの増加
  • 抑制要因
    • 医薬品の承認や製品リコールに関する政府の厳しい規制
  • 機会
    • 細菌感染症に対する政府の好ましい取り組みと政策
    • ドラッグデリバリーの進歩と新薬開発に向けた継続的な研究開発活動
  • 課題
    • カテーテル関連血流感染薬剤に関連するアレルゲンと重大な健康上の懸念
• 市場セグメンテーション分析
  • 薬物クラス：カテーテルによる細菌感染症の治療におけるセファゾリンおよびクロキサシリン薬の広範な利用
  • 適応症：ウイルスおよび寄生虫感染症の効果的な管理と予防および治療への関心の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 カテーテル関連血流感染市場薬剤クラス別

• セファゾリン
• セフタジジム
• クロキサシリン
• ダプトマイシン
• エキノキャンディン
• テイコプラニン
• バンコマイシン

第7章 カテーテル関連血流感染市場：投与経路別

• 注射可能
• オーラル

第8章 カテーテル関連血流感染市場適応症別

• 細菌感染症
• 真菌感染症
• ウイルスおよび寄生虫感染症

第9章 カテーテル関連血流感染市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 南北アメリカのカテーテル関連血流感染市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域のカテーテル関連血流感染市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカのカテーテル関連血流感染市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Citius Pharmaceuticals、感染したカテーテルの救済を目的としたMino-Lokの第3相試験の登録完了を発表
  • BD、Bactiguardと提携し、感染予防フォーリーカテーテルの世界のアクセスを強化
  • DefenCathのFDA承認は、血液透析患者のカテーテル関連血流感染予防における重要な一歩となります。
• 戦略分析と提言

企業一覧

• Advacare Pharma
• AstraZeneca PLC
• Bactiguard AB
• Becton, Dickinson and Company
• CorMedix Inc
• Fresenius Medical Care AG
• Glenmark Pharmaceuticals Ltd.
• IntegraDose Compounding Services, LLC
• Johnson & Johnson Services, Inc
• JoinHub Pharma
• Lupin Ltd.
• Lyka Hetero Healthcare Ltd.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• TauroPhar GmbH
• Xellia Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET RESEARCH PROCESS
• FIGURE 2. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET DYNAMICS
• TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 195. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

The Catheter-related Bloodstream Infections Market was valued at USD 1.64 billion in 2023, expected to reach USD 1.74 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) represent a significant concern in healthcare settings, necessitating ongoing market research into preventive and therapeutic solutions. The scope of CRBSI involves identifying sources, developing preventive strategies, and enhancing treatment protocols, impacting hospitals and healthcare providers aiming to minimize infection rates. This market is crucial due to the rising number of catheter-related procedures and the increased vulnerability of patients in intensive care units. Key applications involve the utilization of advanced antimicrobial catheters, coatings, and lock solutions aimed at reducing infection incidence. End-use primarily spans hospitals, specialty clinics, and outpatient centers. Market growth is driven by technological advancements in catheter designs and coatings that offer improved safety, along with the increasing prevalence of chronic diseases necessitating catheterization.

Key growth influencers include heightened awareness and stringent regulatory guidelines focusing on infection control. There is a substantial opportunity in developing cost-effective and efficient preventive measures and treatments, backed by increasing governmental healthcare expenditures and private investments in research and innovation. However, the market also faces challenges such as high costs associated with advanced medical devices, potential side effects, and the complex nature of R&D for innovative solutions. The latest potential opportunities revolve around the integration of AI and machine learning for predictive analysis in infection risk as well as the development of next-generation biosensors for real-time monitoring of CRBSIs.

For continued growth, businesses should focus on collaborations with healthcare facilities to implement pilot programs testing new technologies and gathering real-world efficacy data. Additionally, exploring partnerships for research funding and innovation grants could further propel market adoption. Nevertheless, limitations such as reimbursement issues and the intricate nature of navigating regulatory pathways could impede rapid development. Innovating in biocompatible and eco-friendly materials for catheters, particularly amid global sustainability trends, presents a promising research area to leverage industry advancement and market penetration. The CRBSI market, though challenging, remains ripe with opportunities for those able to navigate its complexities and invest in forward-thinking solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Catheter-related Bloodstream Infections Market

The Catheter-related Bloodstream Infections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing concerns about intravenous bacterial infections and the need for effective treatment options
  • Growing number of educational campaigns for awareness of catheter-related bloodstream
• Market Restraints
  • Strict government regulations related to drug approvals and cases of product recalls
• Market Opportunities
  • Favorable government initiatives and policies for bacterial infectious diseases
  • Advancements in the drug delivery and ongoing R&D activities for the novel drug development
• Market Challenges
  • Allergens and significant health concerns associated with catheter-related bloodstream infections medications

Porter's Five Forces: A Strategic Tool for Navigating the Catheter-related Bloodstream Infections Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Catheter-related Bloodstream Infections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Catheter-related Bloodstream Infections Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Catheter-related Bloodstream Infections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Catheter-related Bloodstream Infections Market

A detailed market share analysis in the Catheter-related Bloodstream Infections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Catheter-related Bloodstream Infections Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Catheter-related Bloodstream Infections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Catheter-related Bloodstream Infections Market

A strategic analysis of the Catheter-related Bloodstream Infections Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Cefazoline, Ceftazidime, Cloxacillin, Daptomycin, Echinocandin, Teicoplanin, and Vancomycin.
• Based on Route of Administration, market is studied across Injectable and Oral.
• Based on Indication, market is studied across Bacterial Infections, Fungal Infection, and Viral & Parasitic Infections.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
    • 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
  • 5.1.2. Restraints
    • 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
  • 5.1.3. Opportunities
    • 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
    • 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
  • 5.1.4. Challenges
    • 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
  • 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Catheter-related Bloodstream Infections Market, by Drug Class

• 6.1. Introduction
• 6.2. Cefazoline
• 6.3. Ceftazidime
• 6.4. Cloxacillin
• 6.5. Daptomycin
• 6.6. Echinocandin
• 6.7. Teicoplanin
• 6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

• 8.1. Introduction
• 8.2. Bacterial Infections
• 8.3. Fungal Infection
• 8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
  • 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
  • 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Advacare Pharma
• 2. AstraZeneca PLC
• 3. Bactiguard AB
• 4. Becton, Dickinson and Company
• 5. CorMedix Inc
• 6. Fresenius Medical Care AG
• 7. Glenmark Pharmaceuticals Ltd.
• 8. IntegraDose Compounding Services, LLC
• 9. Johnson & Johnson Services, Inc
• 10. JoinHub Pharma
• 11. Lupin Ltd.
• 12. Lyka Hetero Healthcare Ltd.
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Sanofi SA
• 17. TauroPhar GmbH
• 18. Xellia Pharmaceuticals Ltd.